Abstract:Abstract Background Estrogen receptors (ERs) are thought to play an important role in non-small cell lung cancer (NSCLC). However, the effect of ERs in NSCLC is still controversial and needs further investigation. A new consideration is that ERs may affect NSCLC progression through complicated molecular signaling networks rather than individual targets. Therefore, this study aims to explore the effect of ERs in NSCLC from the perspective of cancer systems biology. Methods The gene expression profile of NSCLC samples in TCGA dataset was analyzed by bioinformatics method. Variations of cell behaviors and protein expression were detected in vitro. The kinetic process of molecular signaling network was illustrated by a systemic computational model. At last, immunohistochemical (IHC) and survival analysis was applied to evaluate the clinical relevance and prognostic effect of key receptors in NSCLC. Results Bioinformatics analysis revealed that ERs might affect many cancer-related molecular events and pathways in NSCLC, particularly membrane receptor activation and signal transduction, which might ultimately lead to changes in cell behaviors. Experimental results confirmed that ERs could regulate cell behaviors including cell proliferation, apoptosis, invasion and migration; ERs also regulated the expression or activation of key members in membrane receptor signaling pathways such as epidermal growth factor receptor (EGFR), Notch1 and Glycogen synthase kinase-3β/β-Catenin (GSK3β/β-Catenin) pathways. Modeling results illustrated that the promotive effect of ERs in NSCLC was implemented by modulating the signaling network composed of EGFR, Notch1 and GSK3β/β-Catenin pathways; ERs maintained and enhanced the output of oncogenic signals by adding redundant and positive-feedback paths into the network. IHC results echoed that high expression of ERs, EGFR and Notch1 had a synergistic effect on poor prognosis of advanced NSCLC. Conclusions This study indicated that ERs were likely to promote NSCLC progression by modulating the integrated membrane receptor signaling network composed of EGFR, Notch1 and GSK3β/β-Catenin pathways and then affecting tumor cell behaviors. It also complemented the molecular mechanisms underlying the progression of NSCLC and provided new opportunities for optimizing therapeutic scheme of NSCLC.

Estrogen receptors participate in carcinogenesis signaling pathways by directly regulating NOD-like receptors.

Estrogen receptor alpha regulates the Wnt/β-catenin signaling pathway in colon cancer by targeting the NOD-like receptors

Nlrp3 Inflammasome Activation Of Mast Cells By Estrogen Via The Nuclear-Initiated Signaling Pathway Contributes To The Development Of Endometriosis

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

Lnc-DC Promotes Estrogen Independent Growth and Tamoxifen Resistance in Breast Cancer

Estrogen receptor α aggravates intestinal inflammation via promoting the activation of NLRP3 inflammasome

Estrogen Promotes the Metastasis of Non‑small Cell Lung Cancer Via Estrogen Receptor Β by Upregulation of Toll‑like Receptor 4 and Activation of the Myd88/nf‑κb/mmp2 Pathway.

Estrogen receptor β activation inhibits colitis by promoting NLRP6-mediated autophagy

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Estrogen Receptor Α-Mediated Signaling Inhibits Type I Interferon Response to Promote Breast Carcinogenesis

Estrogen plays an important role by influencing the NLRP3 inflammasome

Toll-Like Receptor 9 Agonist Inhibits Er Alpha-Mediated Transactivation by Activating Nf-Kappa B in Breast Cancer Cell Lines

Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective

Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment

Estrogen receptors in gastric cancer: Advances and perspectives

Estrogen suppresses hepatocellular carcinoma cells through ER β -mediated upregulation of the NLRP3 inflammasome

Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome

Implications of estrogen and its receptors in colorectal carcinoma

Focus on negatively regulated NLRs in inflammation and cancer

Pharmacological Activation of Estrogen Receptor Beta Augments Innate Immunity to Suppress Cancer Metastasis

Estrogen Receptor Β Activation Alleviates Inflammatory Bowel Disease by Suppressing NLRP3-dependent IL-1β Production in Macrophages Via Downregulation of Intracellular Calcium Level